While today's medications may be becoming more affordable, newer therapies are expected to enter the market that may offer greater efficacy , but come with higher costs
Clinical Trial of a Leucotriene B4 Receptor Antagonist, BIIL 284, in Patients With Rheumatoid Arthritis
Our findings suggest that compared to insulin therapy, the higher drug acquisition, pharmacy, and outpatient costs associated with the real-world use of a GLP-1RA is offset by a reduction in healthcare-related expenses associated with emergency room visits and inpatient admissions owing to reduced risks of all-cause mortality and hospitalized hypoglycemia
This can lead to reduced calorie intake and, over time, significant weight loss
GLP-1s are an approved treatment for those with a BMI over 30, or a BMI over 27 with at least one comorbidity like type 2 diabetes, hypertension or sleep apnea
How L-Carnitine Enhances the Keto Diet 1